Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:14 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,851 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Active, not recruiting Not applicable Interventional

Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

NCT00542373
View directory record Official record
Conditions
Erythroplakia, Fanconi Anemia, Lichen Planus, Oral Cavity and Lip Precancerous Condition, Oral Cavity Leukoplakia, Oral Neoplasm, Premalignant Lesion, Tobacco Use Disorder
Interventions
Cytology Specimen Collection Procedure, Diagnostic Microscopy, Diagnostic Procedure, Fluorescence Imaging, Fluorescence Spectroscopy
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02741596
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 1Phase 2 Interventional Results available

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

NCT01506141
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT, Elaprase
Drug
Lead sponsor
Takeda
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Nov 1, 2026, 10:14 PM EST
Completed Not applicable Interventional

Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation

NCT06105541
View directory record Official record
Conditions
Hypermobile Ehlers-Danlos Syndrome, Hypermobile Spectrum Disorder, Ehlers-Danlos Syndrome
Interventions
Transcutaneous Auricular Neurostimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 1Phase 2 Interventional

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

NCT00125333
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
NF-kappaB Decoy
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Miami, Florida • Fridley, Minnesota • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

NCT02791308
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 90 Years
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 2 Interventional

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

NCT06015308
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 3 Interventional Results available

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

NCT00856206
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
77
States / cities
Alabaster, Alabama • Mesa, Arizona • Burbank, California + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

NCT00208026
View directory record Official record
Conditions
Netherton Syndrome
Interventions
Pimecrolimus 1% Cream
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Nov 1, 2026, 10:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Osteogenesis Imperfecta Blood Pressure Study

NCT04169568
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Manual cuff blood pressure
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
1 Year to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Nov 1, 2026, 10:14 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685
View directory record Official record
Conditions
Alport Syndrome
Interventions
BAY 3401016, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Chubbuck, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Terminated Phase 1Phase 2 Interventional

Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions

NCT00129415
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis, Alopecia, Mycosis Fungoides, Urticaria, Dermatoses, Stretch Marks
Interventions
UVA1 Irradiation, UVB Irradiation
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Nov 1, 2026, 10:14 PM EST
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

NCT05695248
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Navenibart
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 1 Interventional

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

NCT06345404
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Soquelitinib, Placebo
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 1 Interventional Results available

A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)

NCT00942084
View directory record Official record
Conditions
Herpes Simplex Virus, Neonatal Sepsis
Interventions
Acyclovir
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 45 Days
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Wichita, Kansas • New Orleans, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Nov 1, 2026, 10:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Risk of Asthma in Infants With Atopic Dermatitis

NCT00459576
View directory record Official record
Conditions
Asthma, Eczema, Dermatitis, Atopic
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Nov 1, 2026, 10:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Clinical Research Core Dental Screening Protocol

NCT00090818
View directory record Official record
Conditions
Oral Mucosal Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 10:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

NCT03511690
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
BRCA-Gist
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Nov 1, 2026, 10:14 PM EST
Completed Phase 2 Interventional

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

NCT05812781
View directory record Official record
Conditions
Cryopyrin Associated Periodic Syndrome
Interventions
VTX2735
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Diego, California • Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Nov 1, 2026, 10:14 PM EST
Recruiting Not applicable Interventional

Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

NCT05994664
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
Heartmath Intervention, Control Group
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Nov 1, 2026, 10:14 PM EST
Completed No phase listed Observational

Diagnostic and Screening Study of Genetic Disorders

NCT00006057
View directory record Official record
Conditions
Tay-Sachs Disease, Porphyria, Erythropoietic, Leukodystrophy, Globoid Cell, Metabolism, Inborn Errors
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 10:14 PM EST